Literature DB >> 20566924

Skin manifestations and vascular endothelial growth factor levels in POEMS syndrome: impact of autologous hematopoietic stem cell transplantation.

Stéphane Barete1, Roger Mouawad, Sylvain Choquet, Karine Viala, Véronique Leblond, Lucile Musset, Zahir Amoura, David Khayat, Camille Francès.   

Abstract

OBJECTIVES: To investigate skin manifestations of the polyneuropathy, organomegaly, endocrinopathy, monoclonal gammopathy, and skin changes (POEMS) syndrome and their correlation with serum vascular endothelial growth factor (s-VEGF-A) levels and to describe the impact of autologous peripheral blood stem cell transplantation (aPBSCT) on these manifestations and the correlation with s-VEGF-A levels.
DESIGN: Case series from January 1993 through June 2007.
SETTING: Hospitalized care in Assistance Publique-Hôpitaux de Paris in Pitié-Salpêtrière and Tenon hospitals. PATIENTS: Twenty-three patients with POEMS syndrome, 10 of whom were clinically followed up after aPBSCT. MAIN OUTCOME MEASURES: Description and distribution of clinical lesions at POEMS syndrome diagnosis, skin evaluation after aPBSCT, and s-VEGF-A levels measured at POEMS syndrome diagnosis and after aPBSCT.
RESULTS: In 21 patients with skin manifestations at POEMS syndrome diagnosis, the most common skin manifestations were hemangiomas (18 patients [86%]), hyperpigmentation (16 [76%]), skin thickening (12 [57%]), acrocyanosis (12 [57%]), hypertrichosis (11 [52%]), acquired facial lipoatrophy (11 [52%]), and white nails (8 [38%]). The median s-VEGF-A level was not different between patients with and without skin manifestations except in those with hypertrichosis (P = .04). After aPBSCT, no significant correlation was observed between s-VEGF-A level decreases and response of skin manifestations, again except for hypertrichosis (P = .007).
CONCLUSIONS: Acquired facial lipoatrophy and livedo should be added to the skin manifestations of POEMS syndrome. Despite a role of s-VEGF-A in various skin manifestations, the impact of s-VEGF-A level decreases on skin outcomes is weak after aPBSCT, mostly resulting in clinical stabilization.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20566924     DOI: 10.1001/archdermatol.2010.100

Source DB:  PubMed          Journal:  Arch Dermatol        ISSN: 0003-987X


  9 in total

1.  [POEMS syndrome. An interdisciplinary clinical challenge].

Authors:  S A Braun; P Albrecht; A Methner; S Hanneken
Journal:  Hautarzt       Date:  2011-10       Impact factor: 0.751

Review 2.  How I treat POEMS syndrome.

Authors:  Angela Dispenzieri
Journal:  Blood       Date:  2012-04-30       Impact factor: 22.113

3.  Advanced POEMS syndrome treated with high-dose melphalan followed by autologous blood stem cell transplantation: a single-center experience.

Authors:  Il-Young Jang; Dok Hyun Yoon; Shin Kim; Kyoungmin Lee; Kwang-Kuk Kim; Young-Min Lim; Won-Ki Min; Cheolwon Suh
Journal:  Blood Res       Date:  2014-03-24

Review 4.  POEMS Syndrome: an Enigma.

Authors:  Rahma Warsame; Uday Yanamandra; Prashant Kapoor
Journal:  Curr Hematol Malig Rep       Date:  2017-04       Impact factor: 4.213

5.  Cutaneous Manifestations in POEMS Syndrome: Case Report and Review.

Authors:  Flauberto Sousa Marinho; Rodrigo Pirmez; Renata Nogueira; Tullia Cuzzi; Celso Tavares Sodré; Marcia Ramos-e-Silva; Marcia Silva
Journal:  Case Rep Dermatol       Date:  2015-04-21

Review 6.  Cutaneous manifestations of monoclonal gammopathy.

Authors:  Jean-Sebastien Claveau; David A Wetter; Shaji Kumar
Journal:  Blood Cancer J       Date:  2022-04-11       Impact factor: 11.037

7.  Polyneuropathy, organomegaly, endocrinopathy, M-protein and skin changes (POEMS syndrome): a paraneoplastic syndrome.

Authors:  Sunil Kumar; Shruti Sharma
Journal:  Oxf Med Case Reports       Date:  2015-03-21

8.  Do you know this syndrome? POEMS syndrome.

Authors:  Guida Santos; Sara Lestre; Alexandre João
Journal:  An Bras Dermatol       Date:  2013 Nov-Dec       Impact factor: 1.896

Review 9.  POEMS SYNDROME: an Update.

Authors:  Andrea Nozza
Journal:  Mediterr J Hematol Infect Dis       Date:  2017-09-01       Impact factor: 2.576

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.